Literature DB >> 33789017

Adjuvant Nivolumab in Esophageal Cancer - A New Standard of Care.

David H Ilson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33789017     DOI： 10.1056/NEJMe2101983

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial.

Authors:  Edward Yu; Alison L Allan; Michael Sanatani; Debra Lewis; Andrew Warner; A Rashid Dar; Brian P Yaremko; Lori E Lowes; David A Palma; Jacques Raphael; Mark D Vincent; George B Rodrigues; Dalilah Fortin; Richard I Inculet; Eric Frechette; Joel Bierer; Jeffery Law; Jawaid Younus; Richard A Malthaner
Journal:  BMC Cancer       Date:  2022-07-08       Impact factor: 4.638

2.  A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer.

Authors:  Huiru Dai; Minling Liu; Xueying Li; Tingwei Li; Wensheng Huang; Jiehao Liao; Yun Li; Shuo Fang
Journal:  World J Surg Oncol       Date:  2022-08-26       Impact factor: 3.253
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.